Intira Jeannie Collins1, Caroline Foster2, Anna Tostevin3, Pat Tookey4, Andrew Riordan5, David Dunn3, D M Gibb1, Ali Judd1. 1. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, UK. 2. Imperial College Healthcare NHS Trust, London, UK. 3. Research Department of Infection and Population Health, University College London, UK. 4. Institute of Child Health, University College London, London, UK. 5. Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom.
Abstract
Background: Increasing numbers of children infected perinatally with human immunodeficiency virus (HIV) are surviving to adolescence and transitioning to adult care, yet there are scarce data on their clinical status at transfer. Methods: We analyzed prospective cohort data from the UK/Ireland national Collaborative HIV Pediatric Study (CHIPS). Clinical status at last pediatric clinic visit prior to transfer was described. Factors associated with higher CD4 cell count and viral load (VL) suppression<400 c/mL among patients on antiretroviral therapy (ART) at transfer were assessed using linear and logistic regression, respectively. Data were matched with the UK HIV Drug Resistance Database (UKHIVDRB) to assess cumulative resistance profiles at transfer. Results: Of 1,907 children followed in CHIPS from 1996 to November 2014, 644 (34%) transferred to adult care: 53% were female, 62% born outside the UK/Ireland, 75% black African. At last pediatric follow-up, median age was 17.4 years [interquartile range 16.5,18.1], 27% had previous AIDS diagnosis, CD4 was 444 cells/mm3 [280, 643], 76% were on ART, 13% off-ART, and 11% ART-naive. Among patients on ART, 74% had VL<400 c/mL. In multivariable analysis, higher CD4 at transfer was associated with younger age, higher CD4 at ART initiation and lower VL at transfer (P ≤ .001). Predictors of viral suppression include no AIDS diagnosis and later year of transfer (P ≤ .05). Of 291 patients with resistance data, 82% had resistance to ≥1 drug class, 56% to ≥2 classes and 12% had triple-class resistance. Conclusion: Three-quarters of adolescents were on stable ART at transfer, of whom 74% were virologically suppressed. The prevalence of triple-class resistance was relatively low at 12%.
Background: Increasing numbers of children infected perinatally with human immunodeficiency virus (HIV) are surviving to adolescence and transitioning to adult care, yet there are scarce data on their clinical status at transfer. Methods: We analyzed prospective cohort data from the UK/Ireland national Collaborative HIV Pediatric Study (CHIPS). Clinical status at last pediatric clinic visit prior to transfer was described. Factors associated with higher CD4 cell count and viral load (VL) suppression<400 c/mL among patients on antiretroviral therapy (ART) at transfer were assessed using linear and logistic regression, respectively. Data were matched with the UK HIV Drug Resistance Database (UKHIVDRB) to assess cumulative resistance profiles at transfer. Results: Of 1,907 children followed in CHIPS from 1996 to November 2014, 644 (34%) transferred to adult care: 53% were female, 62% born outside the UK/Ireland, 75% black African. At last pediatric follow-up, median age was 17.4 years [interquartile range 16.5,18.1], 27% had previous AIDS diagnosis, CD4 was 444 cells/mm3 [280, 643], 76% were on ART, 13% off-ART, and 11% ART-naive. Among patients on ART, 74% had VL<400 c/mL. In multivariable analysis, higher CD4 at transfer was associated with younger age, higher CD4 at ART initiation and lower VL at transfer (P ≤ .001). Predictors of viral suppression include no AIDS diagnosis and later year of transfer (P ≤ .05). Of 291 patients with resistance data, 82% had resistance to ≥1 drug class, 56% to ≥2 classes and 12% had triple-class resistance. Conclusion: Three-quarters of adolescents were on stable ART at transfer, of whom 74% were virologically suppressed. The prevalence of triple-class resistance was relatively low at 12%.
Authors: C Dollfus; J Le Chenadec; A Faye; S Blanche; N Briand; C Rouzioux; J Warszawski Journal: Clin Infect Dis Date: 2010-07-15 Impact factor: 9.079
Authors: Allison L Agwu; Lana Lee; John A Fleishman; Cindy Voss; Baligh R Yehia; Keri N Althoff; Richard Rutstein; W Christopher Mathews; Ank Nijhawan; Richard D Moore; Aditya H Gaur; Kelly A Gebo Journal: J Adolesc Health Date: 2015-03 Impact factor: 5.012
Authors: Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: Caroline Foster; Ali Judd; Pat Tookey; Gareth Tudor-Williams; David Dunn; Delane Shingadia; Karina Butler; Mike Sharland; Di Gibb; Hermione Lyall Journal: AIDS Patient Care STDS Date: 2009-03 Impact factor: 5.078
Authors: Kunjal Patel; Miguel A Hernán; Paige L Williams; John D Seeger; Kenneth McIntosh; Russell B Van Dyke; George R Seage Journal: Clin Infect Dis Date: 2008-06-01 Impact factor: 9.079
Authors: Ali Judd; Katja Doerholt; Pat A Tookey; Mike Sharland; Andrew Riordan; Esse Menson; Vas Novelli; E G Hermione Lyall; Janet Masters; Gareth Tudor-Williams; Trinh Duong; Di M Gibb Journal: Clin Infect Dis Date: 2007-08-27 Impact factor: 9.079
Authors: Ali Judd; Caroline Foster; Lindsay C Thompson; Kate Sturgeon; Marthe Le Prevost; Eva Jungmann; Katie Rowson; Hannah Castro; Diana M Gibb Journal: PLoS One Date: 2018-10-12 Impact factor: 3.240
Authors: Anne M Neilan; Audrey C Bangs; Michael Hudgens; Kunjal Patel; Allison L Agwu; Ingrid V Bassett; Aditya H Gaur; Emily P Hyle; Catherine M Crespi; Keith J Horvath; Caitlin M Dugdale; Kimberly A Powers; H Jonathon Rendina; Milton C Weinstein; Rochelle P Walensky; Kenneth A Freedberg; Andrea L Ciaranello Journal: AIDS Behav Date: 2021-02-06